Bellicum Pharmaceuticals (BLCM)

Bellicum Pharmaceuticals (BLCM) Income Statement


Bellicum Pharmaceuticals Income Statement

Last quarter (Q3 2022), Bellicum Pharmaceuticals's total revenue was $1.00M, a decrease of -80.00% from the same quarter last year. In Q3, Bellicum Pharmaceuticals's net income was $-7.21M. See Bellicum Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 1.50M$ 6.20M$ 500.00K$ 7.14M$ 1.12M$ 185.00K
Cost of Revenue
Gross Profit
Operating Expense
$ 26.24M$ 30.59M$ 54.58M$ 94.51M$ 96.59M$ 87.57M
Operating Income
$ -24.74M$ -24.39M$ -54.08M$ -87.36M$ -95.47M$ -87.39M
Net Non Operating Interest Income Expense
$ 46.00K$ 28.00K$ -2.27M$ -2.93M$ -2.56M$ -2.62M
Other Income Expense
$ 8.45M$ 14.65M$ 48.63M$ -22.18M$ -10.00K$ -1.77M
Pretax Income
$ -16.25M$ -9.71M$ -7.72M$ -112.48M$ -98.04M$ -91.78M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -16.25M$ -9.71M$ -7.72M$ -112.48M$ -98.04M$ -91.78M
Basic EPS
$ -0.49$ -0.84$ -1.34$ -24.01$ -24.37$ -28.90
Diluted EPS
$ -0.50$ -0.84$ -1.34$ -24.01$ -24.37$ -28.90
Basic Average Shares
$ 108.24M$ 11.50M$ 5.76M$ 4.68M$ 4.02M$ 3.17M
Diluted Average Shares
$ 108.24M$ 11.50M$ 5.76M$ 4.68M$ 4.02M$ 3.17M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 26.24M$ 30.59M$ 54.58M$ 94.51M$ 96.59M$ 87.57M
Net Income From Continuing And Discontinued Operation
$ -16.25M$ -9.71M$ -7.72M$ -112.48M$ -98.04M$ -91.78M
Normalized Income
$ -22.63M$ -24.35M$ -56.35M$ -93.28M$ -98.04M$ -90.00M
Interest Expense
-$ 4.00K$ 2.66M$ 4.28M$ 4.20M$ 3.67M
$ -16.25M$ -9.70M$ -5.06M$ -108.20M$ -93.84M$ -88.11M
$ -16.22M$ -9.56M$ -3.19M$ -99.69M$ -87.14M$ -84.54M
Currency in USD

Bellicum Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis